By Clinical Informatics News Staff

August 4, 2017 | TrialScope yesterday launched Core Disclosure, enabling teams to approve disclosure content once and then reuse the disclosure data around the globe. The product is intended to promote a new level of data efficiency accuracy and alignment.

Disclosing the same data on multiple registries drains time and resources and adds unneeded risk for sponsors. Core Disclosure addresses the need to streamline the disclosure process and eliminate wasted time and resources. Core Disclosure delivers a configurable list of fields along with simplified data entry; offers a single master protocol form that lists key, common data elements across ClinicalTrials.gov and EudraCT; lets users import and export ClinicalTrials.gov and EudraCT xml; and serves as a unified system to alert the user if data entry would cause an error in ClinicalTrials.Gov or EudraCT

“Core Disclosure is a market-driven solution that was developed in consultation with our community of disclosure professionals,” said Mark Heinold, TrialScope’s Chief Executive Officer in a press release. “As trial disclosure regulations increase, we are thrilled to offer sponsors a solution to streamline the process, allowing them to put the focus back on their trial.”

Core Disclosure, which can be purchased as a standalone solution, was designed to fully integrate with TrialScope’s other suite of offerings, including ATLAS and PharmaCM.